Background {#Sec1}
==========

Evidence suggests that older patients can benefit from aggressive therapies as much as younger individuals can, improving their overall and disease-free survival \[[@CR1]\]. Nevertheless, a high percentage of older patients do not receive standard cancer treatments \[[@CR2]--[@CR5]\]. A European study found that 69% of patients under 65 years old and only 16% of those over this age received adjuvant chemotherapy for stage III colon cancer \[[@CR4]\]. Several authors have shown that these differences remain after adjusting for comorbidity \[[@CR2], [@CR6]\]. Age has also been associated with the frequency of use of radiotherapy \[[@CR7]--[@CR9]\]. In Sweden, preoperative radiotherapy for rectal cancer was given to 64% of patients under 65 years old, to 50% of 65 to 79 years old and to 15% of those 80 years of age or older \[[@CR7]\]. In Canada, Eldin et al. observed that after adjusting for comorbidity and stage, age was the most important factor in determining the use of radiotherapy \[[@CR9]\]. Most of the revised studies have reported results adjusting for comorbidity and stage, but studies are scarce that in addition have adjusted for the patient's social position and living arrangements. None of the multicentre studies has taken into account the inter-hospital variability both in clinical practice and in hospital area's material deprivation.

A greater toxicity of chemotherapy and radiotherapy in older patients with colorectal cancer might explain a lower adherence to clinical practice guidelines. Further, the exclusion of older patients from clinical trials means that there is limited scientific evidence concerning the efficacy and toxicity associated with treatments in this population. This has led to a lack of evidence-based clinical guidelines \[[@CR3]\]. For tumours at some anatomical sites, radiation therapy has been found to be more toxic in patients of advanced ages, suggesting a need for closer monitoring \[[@CR1]\]. Nevertheless, the majority of clinical trials including older patients with colorectal cancer have reported toxicity profiles similar to those observed in younger patients \[[@CR10], [@CR11]\]. In addition to these clinical factors, there are social factors that may place older patients at a disadvantage with respect to receiving treatments, such as having a lower socioeconomic level \[[@CR12]--[@CR14]\] and a lower level of education \[[@CR15]\], as well as more frequently living alone \[[@CR16]\].

The aims of this paper were a) to identify whether there are differences between age groups in the use of chemotherapy for stage III colon cancer and preoperative radiotherapy for stage II and III rectal cancer; and b) to assess whether these differences remain after adjusting for comorbidity, tumour characteristics, curative resection and social factors such as economic deprivation or living arrangements.

Methods {#Sec2}
=======

Data were obtained by conducting a prospective multicentre cohort study in 22 hospitals in five autonomous regions in Spain. We included patients with primary invasive colon or rectal cancer who underwent programmed or urgent surgery between April 2010 and December 2012. A detailed protocol was published by Quintana et al. \[[@CR17]\]. Among the 3315 patients who met the inclusion criteria, 41 were excluded from the study due to poor physical or cognitive status, and we failed to contact another 288. In addition, 237 (7.2%) declined to participate in the study (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flowchart of patients through the study and reasons for non-inclusion

Outcomes and covariates {#Sec3}
-----------------------

The primary outcomes analysed were the use of adjuvant chemotherapy in stage III colon cancer and preoperative radiotherapy in stage II and III rectal cancer. Age was assessed at the time of diagnoses and arbitrarily categorized into three groups: younger (under 65 years of age), older (65 to 80 years) and oldest (over 80 years) patients.

We assessed prognostic factors, which according to the scientific literature, might be unevenly distributed between age groups: a) Social and economic variables: socioeconomic level, considering level of education and area of residence deprivation, which was calculated following the methodology of Esnaola et al. \[[@CR18]\], for each census tract based on five 2001 census indicators related to occupation and educational attainment; living arrangements (alone or with others);

b\) health behaviours: alcohol intake (greater than 80 g/day or not) and smoking habits (current smoker, ex-smoker, never smoker);

c\) cancer family history and whether the diagnosis had been made through a screening programme or not;

d\) health status: comorbidities, measured using the Charlson comorbidity index (CCI) \[[@CR19]\], stratifying patients into three groups (0, 1, and 2 or more), and the American Society of Anesthesiologists (ASA) class \[[@CR20]\], a proxy for the severity of patients' comorbidities;

e\) tumour characteristics: site (proximal colon, distal colon, rectosigmoid junction or rectum), histological findings (adenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, others), degree of differentiation (low, corresponding to tumours that are well or moderately well differentiated, or high, corresponding to poorly differentiated and undifferentiated tumours); h) tumour stage (according to the 7th edition of the TNM classification of the Union for International Cancer Control), assigning patients who underwent neoadjuvant treatment a clinical stage and those who underwent surgery as the first treatment a pathological stage, for statistical analysis;

f\) surgery: profile of the surgeon (fully dedicated to coloproctology or not); type of surgery (elective/emergency); curative resection (no residual tumour (R0) or microscopic/macroscopic remnant of the tumour (R1/R2)); and finally whether a cancer committee was involved in the patient's management, as a process indicator.

Statistical analysis {#Sec4}
--------------------

First, potential prognostic factors were compared among the three age groups using Pearson chi-square test (χ^2^) and chi square test for trends (χ^2^~trends~). Then, the univariate association of each factor with the use of adjuvant chemotherapy and preoperative radiotherapy was investigated using Pearson chi square test for the categorical non ordinal variables and chi square test for trends for the ordinal variables. Multivariable analyses were performed with Generalised Estimating Equations, clustering by hospital, to assess the association between age and the use of chemotherapy and preoperative radiotherapy, adjusting for sociodemographic and clinical factors. This approach enabled us to construct multivariate models that take into account the correlation between individuals from the same hospital. An unstructured variance-covariance matrix was used. Potential confounders with *p* \< 0.2 in the univariate analysis were entered simultaneously in the multivariable model using dummy variables. Missing data were imputed using the multiple imputation method available in SPSS which uses by default 5 iterations. The imputed variables were: level of education, deprivation index, screening, ASA class and alcohol intake. The variables used for the imputation were as follows: age, level of education, deprivation index, autonomous region, CCI, ASA class, alcohol intake and surgeon profile. The calculated measure of association was the odds ratio with the corresponding 95% confidence interval. Two-tailed tests were used, considering *p* values \< 0.05 to be statistically significant. The analysis was performed using IBM SPSS, Statistics for Windows, v23, and Stata v14.

Results {#Sec5}
=======

A total of 2749 patients were finally included in the study, among whom 654 had stage III colon cancer and 503 stage II or III rectal cancer (Fig. [1](#Fig1){ref-type="fig"}). This research report refers to these 1157 patients.

Patients included were significantly older than those who were excluded or not contactable (p, χ^2^ \< 0.005), but differences with those who declined to participate were not statistically significant.

Of the included patients, 38.8% were under 65 years, 47.2% were between 65 and 80 years, and 13.9% were over 80 years of age. Approximately two thirds (65.2%) were men. Overall, 13% had not completed any formal education, and only 12% had university qualifications (short- or long-cycle degrees). Most participants (86%) lived with a relative.

Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} indicate the observed differences between age groups, for colon and rectum respectively. Older patients were more likely to have a low education level (p, χ^2^~trends~ \< 0.0005) and to live alone (p, χ^2^ \< 0.0005). No significant differences were found in deprivation of the area of residence (*p* = 0.9). Younger patients were more likely to report a family history of cancer (p, χ^2^ \< 0.05). The proportion of patients who have never smoked increases with age (p, χ^2^ \< 0.05) and comorbidity increases with age (p, χ^2^~trends~ \< 0.0005). In colon cancer there were no age significant differences in tumour sites, histological classification, degree of differentiation or, in rectal cancer, in stage at diagnosis. Finally, we did not find differences in curative resections (R0) by age.Table 1Distribution of social, health and clinical patient's variables by age groups in stage III colon cancer (*n* = 654)N\<  65 years\
*N* = 246\
n (%)65--80 years\
*N* = 311\
n (%)\>  80 years\
*N* = 97\
n (%)*P* value^a^Sociodemographic variablesSex654 Male151 (61.4)205 (65.9)60 (61.9)0.50 Female95 (38.6)106 (34.1)37 (38.1)0.65Deprivation index624 Quartile 1 least deprived49 (21.2)67 (22.3)17 (18.5)0.67 Quartile 264 (27.7)101 (33.6)31 (33.7)0.78 Quartile 367 (29.0)72 (23.9)22 (23.9) Quartile 4 most deprived51 (22.1)61 (20.3)22 (23.9)Level of education534 Illiterate or with no formal education10 (4.8)46 (18.2)15 (20.5)\< 0.0005 Primary123 (59.1)162 (64.0)50 (68.5)\< 0.0005 Secondary35 (16.8)24 (9.5)3 (4.1) University40 (19.2)21 (8.3)5 (6.8)Living arrangements522 Living alone23 (11.5)42 (17.0)14 (18.7)0.18 Living with others177 (88.5)205 (83.0)61 (81.3)0.08Family history of cancer584 No118 (52.2)175 (63.9)68 (81.0)\< 0.0005 Yes108 (47.8)99 (36.1)16 (19.0)\< 0.0005Screening622 No174 (74.0)250 (84.7)86 (93.5)\< 0.0005 Yes61 (26.0)45 (15.3)6 (6.5)\< 0.0005Health behaviours and comorbiditiesSmoking habits648 Never smoker112 (45.5)154 (50.0)50 (53.2)0.01 Current smoker42 (17.1)31 (10.1)4 (4.3)0.79 Ex-smoker92 (37.4)123 (39.9)40 (42.6)Alcohol612 No188 (83.9)257 (86.2)84 (93.3)0.09 Yes36 (16.1)41 (13.8)6 (6.7)0.04ASA class633 I-II175 (73.2)157 (52.2)30 (32.3)\< 0.0005 III60 (25.1)127 (42.2)52 (55.9)\< 0.0005 IV4 (1.7)17 (5.6)11 (11.8)Charlson Index654 0163 (66.3)158 (50.8)40 (41.2)\< 0.0005 149 (19.9)80 (25.7)26 (26.8)\< 0.0005  ≥ 234 (13.8)73 (23.5)31 (32.0)Tumour characteristicsSite654 Rectosigmoid junction40 (16.3)45 (14.5)11 (11.3)0.72 Distal colon108 (43.9)140 (45.0)41 (42.3)0.21 Proximal colon98 (39.8)126 (40.5)45 (46.4)Histological classification643 Adenocarcinoma219 (91.3)274 (89.3)87 (90.6)0.18 Mucinous adenocarcinoma16 (6.7)27 (8.8)9 (9.4)0.69 Signet-ring cell carcinoma2 (0.8)6 (2.0)0 (0.0) Other types of carcinoma3 (1.3)0 (0.0)0 (0.0)Degree of differentiation573 Low grade165 (79.3)226 (81.9)79 (88.8)0.15 High grade43 (20.7)50 (18.1)10 (11.2)0.07InterventionMain intervention654 Elective232 (94.3)300 (96.5)87 (89.7)0.03 Emergency14 (5.7)11 (3.5)10 (10.3)0.32Curative resection618 R0218 (92.4)261 (90.0)84 (91.3)0.63 R1 / R218 (7.6)29 (10.0)8 (8.7)0.56Surgeon's profile615 General61 (27.0)96 (32.5)36 (38.3)0.12 Coloproctologist165 (73.0)199 (67.5)58 (61.7)0.04Cancer committee617 No77 (32.9)127 (43.6)44 (47.8)0.01 Yes157 (67.1)164 (56.4)48 (52.2)0.004^a^Pearson Chi-square test to generate upper *P* value and chi-square test for trends to generate lower *P* valueTable 2Distribution of social, health and clinical patient's variables by age groups in stage II, III rectal cancer (*n* = 503)^a^N\<  65 years\
*N* = 203\
n (%)65--80 years\
*N* = 235\
n (%)\>  80 years\
*N* = 64\
n (%)*P* value^b^Sociodemographic variablesSex502 Male128 (63.1)169 (71.9)41 (64.1)0.12 Female75 (36.9)66 (28.1)23 (35.9)0.35Deprivation index476 Quartile 1 least deprived28 (14.7)41 (18.6)12 (18.8)0.66 Quartile 268 (35.6)72 (32.6)16 (25.0)0.80 Quartile 357 (29.8)71 (32.1)24 (37.5) Quartile 4 most deprived38 (19.9)37 (16.7)12 (18.8)Level of education408 Illiterate or with no formal education9 (5.3)30 (15.9)11 (22.4)\< 0.0005 Primary100 (58.8)137 (72.5)33 (67.3)\< 0.0005 Secondary34 (20.0)8 (4.2)1 (2.0) University27 (15.9)14 (7.4)4 (8.2)Living arrangements403 Living alone11 (6.7)30 (15.8)9 (18.8)0.01 Living with others154 (93.3)160 (84.2)39 (81.3)0.005Family history of cancer464 No97 (51.9)126 (58.3)42 (68.9)0.06 Yes90 (48.1)90 (41.7)19 (31.1)0.02Screening478 No167 (87.0)199 (88.8)58 (93.5)0.36 Yes25 (13.0)25 (11.2)4 (6.5)0.18Health behaviours and comorbiditiesSmoking habits498 Never smoker82 (40.4)104 (44.8)37 (58.7)0.001 Current smoker49 (24.1)30 (12.9)3 (4.8)0.37 Ex-smoker72 (35.5)98 (42.2)23 (36.5)Alcohol483 No175 (89.3)198 (87.2)56 (93.3)0.39 Yes21 (10.7)29 (12.8)4 (6.7)0.70ASA class490 I-II144 (73.1)118 (51.5)31 (48.4)\< 0.0005 III51 (25.9)101 (44.1)31 (48.4)\< 0.0005 IV2 (1.0)10 (4.4)2 (3.1)Charlson Index502 0134 (66.0)118 (50.2)25 (39.1)\< 0.0005 143 (21.2)60 (25.5)18 (28.1)\< 0.0005  ≥ 226 (12.8)57 (24.3)21 (32.8)Tumour characteristicsHistological classification467 Adenocarcinoma181 (96.8)201 (92.6)58 (92.1)0.05 Mucinous adenocarcinoma5 (2.7)16 (7.4)4 (6.3)0.05 Signet-ring cell carcinoma1 (0.5)0 (0.0)0 (0.0) Other types of carcinoma0 (0.0)0 (0.0)1 (1.6)Degree of differentiation389 Low grade137 (86.7)153 (86.0)48 (90.6)0.68 High grade21 (13.3)25 (14.0)5 (9.4)0.62Stage at diagnosis (pTNM or cTNM)502 II61 (30.0)76 (32.3)27 (42.2)0.19 III142 (70.0)159 (67.7)37 (57.8)0.11InterventionMain intervention502 Elective200 (98.5)234 (99.6)64 (100.0)0.35 Emergency3 (1.5)1 (0.4)0 (0.0)0.16Curative resection476 R0162 (84.4)193 (85.4)52 (89.7)0.60 R1/R230 (15.6)33 (14.6)6 (10.3)0.37Surgeon's profile476 General59 (30.3)71 (32.3)18 (29.5)0.87 Coloproctologist136 (69.7)149 (67.7)43 (70.5)0.92Cancer committee418 No52 (27.2)74 (33.2)19 (29.7)0.42 Yes139 (72.8)149 (66.8)45 (70.3)0.42^a^Age was missing in a case^b^Pearson Chi-square test to generate upper *P* value and chi-square test for trends to generate lower *P* value

Among the main differences in colon and rectal cancer, we highlight the following: younger patients were more likely to have undergone screening (p, χ^2^ \< 0.0005) in colon cancer but there were no significant differences in rectal cancer; among those with colon cancer, patients over 80 years of age were more likely to have had emergency surgery (p, χ^2^ = 0.04) compared with those under age 80; with increasing age, the number of surgical interventions done by surgeons specialized in coloproctology decreased (p, χ^2^~trends~ = 0.04) and the proportion of cases reviewed by an interdisciplinary tumor committee decreased (p, χ^2^~trends~ = 0.004). These differences were not observed among those with rectal cancer.

Table S1 reports the frequencies of imputed variables before and after imputation. The distribution of the imputed values can be seen to be homogenous (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Adjuvant chemotherapy for patients with colon cancer {#Sec6}
----------------------------------------------------

Of the 654 patients with stage III colon or rectosigmoid cancer identified, 75% received chemotherapy after surgical resection. Table [3](#Tab3){ref-type="table"}A summarises the univariate association of patient characteristics with chemotherapy. The use of this therapy decreased significantly with age, from 91.9% in the youngest age group to 76.7% in the older group to only 26.8% in the oldest patients (p, χ^2^~trends~ \< 0.0005). No significant difference in use of adjuvant chemotherapy was observed by sex. A higher level of comorbidity was also associated with less use of chemotherapy, with a rate of 82% in patients with no comorbidities falling to just 58.7% in those with a CCI of 2 or more. Nevertheless, we should note that even among patients with no comorbidities, older age was also associated with less use of chemotherapy; the rates were 94, 82 and 33% for those under 65, between 65 and 80, and over 80 years of age, respectively (p, χ^2^~trends~ \< 0.0005) (Fig. [2](#Fig2){ref-type="fig"}). Table [3](#Tab3){ref-type="table"}B shows the multivariable results. There was a significant negative association between age and the use of chemotherapy after simultaneously adjusting for comorbidity, tumour characteristics (such as the site and degree of differentiation) and level of education. Compared to younger patients, the adjusted OR was 0.3 (95% CI: 0.1--0.6) for the older and 0.04 (95% CI: 0.02--0.09) for the oldest age groups. We found no significant association between chemotherapy use and either participation of the cancer committee in the management of the patient or the surgeon's specialisation. The outcome of the surgery did not have a significant effect on the chemotherapy use.Table 3Crude and adjusted analysis of the association between age and adjuvant chemotherapy in stage III colon cancerAdjuvant chemotherapy for stage III colon cancer3A. Univariate analysis3B. Multivariate analysisn (%)*P* valueOdds Ratio (95% CI)*P* valueAge, years  \< 65226 (91.9)\< 0.0005^b^1 65--80239 (76.8)0.3 (0.1--0.6)0.001  \> 8026 (26.8)0.04 (0.02--0.09)\< 0.0005Sex Male309 (74.3)0.57^a^ Female182 (76.5)Deprivation index Quartile 1106 (79.7)0.29^b^ Quartile 2142 (72.4) Quartile 3121 (75.2) Quartile 497 (72.4)Level of education No formal47 (66.2)\< 0.0005^b^1 Primary253 (75.5)1.2 (0.7--2.2)0.46 Secondary53 (85.5)1.6 (0.4--5.5)0.46 University59 (89.4)1.6 (0.5--5.7)0.45Living arrangement Living alone56 (70.9)0.2^a^ Living with others345 (77.9)Family history of cancer No257 (71.2)\< 0.0005^a^1 Yes194 (87.0)1.9 (0.7--5.0)0.21Screening No368 (72.2)0.001^a^1 Yes97 (86.6)1.0 (0.4--2.2)0.99Smoking habits Never smoker241 (76.3)0.516^a^ Current smoker61 (79.2) Ex-smoker187 (73.3)Alcohol No392 (74.1)0.42^a^ Yes63 (75.9)Charlson index 0296 (82.0)\< 0.0005^b^1 1114 (73.5)0.8 (0.5--1.4)0.43  ≥ 281 (58.7)0.6 (0.3--1.2)0.17ASA class I-II309 (85.4)\< 0.0005^b^1 III155 (64.9)0.6 (0.3--1.1)0.10 IV10 (31.3)0.1 (0.03--0.3)\< 0.0005Site Rectosigmoid junction78 (81.3)0.19^a^1 Distal colon219 (75.8)0.5 (0.2--1.4)0.18 Proximal colon194 (72.1)0.5 (0.2--1.6)0.25Degree of differentiation Low grade354 (75.3)0.12^a^1 High grade85 (82.5)1.2 (0.4--3.4)0.70Histological classification Adenocarcinoma439 (75.7)0.29^a^ Mucinous Adenocarcinoma38 (73.1) Signet-ring cell carcinoma8 (100.0) Other carcinomas3 (100.0)Cancer committee No180 (72.6)0.30^a^ Yes282 (76.4)Surgeon's profile General134 (69.4)0.07^a^1 Coloproctologist323 (76.5)1.3 (0.6--3.1)0.50Curative resection R0428 (76.0)0.62^a^ R1/R240 (72.7)^a^Pearson Chi-square test^b^Chi-square test for trendsFig. 2Percentage of patients with stage III colon cancer who received chemotherapy by age and number of comorbidities. Legend: Age (years) ![](12885_2019_5910_Figa_HTML.gif){#d29e3885} \< 65, ![](12885_2019_5910_Figb_HTML.gif){#d29e3888} 65--80, ![](12885_2019_5910_Figc_HTML.gif){#d29e3891} \> 80

The most frequent chemotherapy schemes were CAPOX (capecitabine, oxaliplatin) in 49.4% of patients, FOLFOX (5- Fluorouracil, oxaliplatin) in 26.9% and capecitabine in monotherapy in 20% of the cases. Oxaliplatin-based adjuvant chemotherapy administration varied with age as follows: 83.4% in the younger group, 64.2% in the older and 29% in the oldest (p, χ^2^~trends~ \< 0.0005). The administration of capecitabine in monotherapy was 11.7, 24.6 and 57.9%, respectively, (p, χ^2^~trends~ \< 0.0005).

Preoperative radiotherapy for patients with rectal cancer {#Sec7}
---------------------------------------------------------

Of the 503 patients with stage II and III rectal cancer, 61% received radiotherapy before surgical intervention. Table [4](#Tab4){ref-type="table"}A shows the univariate association of patient characteristics with preoperative radiotherapy. It was observed that its use decreased significantly with age, from 68% in the youngest age group to 60.4% in the older to 42.2% in the oldest patients (p, χ^2^~trends~ \< 0.0005). No significant association was observed between preoperative radiotherapy and sex or with socioeconomic characteristics or living arrangements. We also found significant differences in patients with no comorbidities, with rates of use of 70, 64 and 40% in the three age groups, respectively (p, χ^2^~trends~ = 0.009) (Fig. [3](#Fig3){ref-type="fig"}). After simultaneously adjusting for family history of cancer, comorbidities and their severity, and tumour stage (Table [4](#Tab4){ref-type="table"}B), age remained the main predictor. Compared to younger patients, the adjusted OR for the oldest patients was 0.5 (95% CI: 0.3--0.8), while the odds in the group of patients aged 65 to 80 years was not significantly lower with respect to the youngest group. We found no association of CCI or ASA with the use of radiotherapy, but family history was associated with a higher odds of use (OR = 1.5, 95% CI: 1.0--2.2), as was the tumour stage (OR = 2.8, 95% CI: 1.5--4.9).Table 4Crude and adjusted analysis of the association between age and preoperative radiotherapy in stage II and III rectal cancer patientsPreoperative radiotherapy in stage II and III rectal cancer4A. Univariate analysis4B. Multivariate analysisn (%)*P* valueOdds Ratio (95% CI)*P* valueAge, years  \< 65138 (68.0)\< 0.0005^b^1 65--80142 (60.4)0.9 (0.6--1.4)0.74  \> 8027 (42.2)0.5 (0.3--0.8)0.004Sex Male205 (60.7)0.85^a^ Female102 (61.8)Deprivation index Quartile 150 (61.7)0.31^b^ Quartile 286 (54.8) Quartile 394 (61.8) Quartile 457 (65.5)Level of education No formal31 (62.0)0.78^b^ Primary164 (60.5) Secondary28 (65.1) University25 (55.6)Living arrangements Living alone30 (60.0)0.88^a^ Living with others217 (61.3)Family history of cancer No147 (55.3)0.005^a^1 Yes136 (68.3)1.5 (1.0--2.1)0.05Screening No262 (61.6)0.30^a^ Yes29 (53.7)Smoking habits Never smoker136 (60.7)0.31^a^ Current smoker56 (68.3) Ex-smoker113 (58.5)Alcohol No264 (61.4)0.77^a^ Yes32 (59.3)Charlson index 0179 (64.6)0.03^b^1 174 (60.7)0.9 (0.6--1.4)0.77  ≥ 254 (51.9)0.9 (0.5--1.7)0.88ASA class I-II187 (63.8)0.12^b^1 III106 (57.6)0.9 (0.6--1.2)0.39 IV7 (50.0)0.8 (0.3--2.4)0.68Degree of differentiation Low grade201 (59.5)0.76^a^ High grade29 (56.9)Histological classification Adenocarcinoma268 (60.8)0.29^a^ Mucinous adenocarcinoma13 (52.0)Stage II75 (45.7)\< 0.0005^a^1 III232 (68.4)2.8 (1.5--4.9)0.001Cancer committee No84 (57.9)0.48^a^ Yes205 (61.6)Surgeon's profile General91 (61.1)1.0^a^ Coloproctologist201 (61.3)^a^Pearson Chi-square test^b^Chi-square test for trendsFig. 3Percentage of patients with stage II and III rectal cancer who received preoperative radiotherapy by age and number of comorbidities. Legends: Age (years) ![](12885_2019_5910_Figd_HTML.gif){#d29e4568} \< 65, ![](12885_2019_5910_Fige_HTML.gif){#d29e4571} 65--80, ![](12885_2019_5910_Figf_HTML.gif){#d29e4574} \> 80

Discussion {#Sec8}
==========

Chemotherapy {#Sec9}
------------

In our cohort of patients treated between 2010 and 2012, we found that 70% of all stage III patients with colon cancer received chemotherapy; however, its use dramatically decreased with age, with a percentage of 92% in under-65-year-olds but only 27% among over-80-year-olds. Data from Europe and Australia, where there are health systems with quasi-universal coverage as in Spain, indicate that no more than 20--25% of patients over 75 years old received adjuvant chemotherapy in 2000. In the USA, these percentages reach 40 to 50% \[[@CR21]\]. In Spain, on the basis of population data, a study reported that the percentages of chemotherapy use fall from 61% in under-75-year-olds to 27% in patients 75 years of age or older \[[@CR22]\].

In our study, a quarter of patients between 65 and 80 years old did not receive any chemotherapy. In some patients, this is attributable to a higher level of comorbidity, but we observed that the pattern remains even in patients with no comorbidities. Moreover, variables such as high alcohol intake, tumour characteristics (site and histological findings), and even curative resection had less influence than age on the decision of whether to treat. This is consistent with previous scientific reviews that have demonstrated a lower use of chemotherapy among the older even after adjusting for comorbidity and other relevant clinical variables \[[@CR2], [@CR21]\].

A low level of education, area of residence deprivation and marital status have been reported to be associated with lower probability of treatment \[[@CR15], [@CR23], [@CR24]\]. In our study, we have observed that the magnitude of the association between age and chemotherapy does not change when we adjust for level of education, which means that the lower level of education in older patients does not help to explain the differences observed by age group. The deprivation index and living arrangement were also not found to be significantly associated with the use of chemotherapy.

In agreement with previous authors, we observed that those older than 65 were less likely to be treated with chemotherapy in spite of its survival advantage \[[@CR25], [@CR26]\]. Furthermore, the very old patients who received chemotherapy were more likely to be treated with capecitabine in monotherapy. Further research needs to be done in the oldest age groups, who have been excluded from most clinical trials and for whom little knowledge on treatment efficacy and safety is available \[[@CR27]\].

Preoperative radiotherapy {#Sec10}
-------------------------

The percentages of use of preoperative radiotherapy among patients under 65, between 65 and 80 and over 80 years of age were 68, 60 and 42%, respectively. The decrease with increasing age remained significant after adjusting for comorbidities and the other covariates. Compared to patients under 65 years of age, the adjusted ORs for patients between 65 and 80 and those over 80 years of age were 0.9 and 0.5, respectively.

Previously available evidence, derived from population-level data, indicated less use of radiotherapy among older patients. In Spain, 24% of under-75-year-olds and 11% of patients 75 years of age or older with colorectal cancer have received radiotherapy \[[@CR22], [@CR28]\]. In Sweden, the use of preoperative radiotherapy falls from 64% in under-65-year-olds to 15% in over-80-year-olds \[[@CR7]\]. According to a review by Faivre \[[@CR21]\], the rates of pre- and post-operative radiotherapy ranged from 20 to 50% in different registries in Europe and the USA.

In our study, comorbidity, area of residence deprivation, education and living arrangements did not predict the decision to treat preoperatively with radiotherapy. We did not find studies that analysed the influence of comorbidities. Previous studies have reported living arrangements and marital status to be significant predictors of the use of radiotherapy \[[@CR7], [@CR15], [@CR29]\]. We should note that in our study, the percentage of older patients who lived alone was very low (14%). In other countries, the figures reach 35% in people above 65 years old and 50% in those above 80 years of age. This reflects the level of family support, especially from offspring, for widows/widowers in Spain. In Sweden, a study reported an association with income but not with level of education \[[@CR7]\].

Another potentially relevant factor is the distance from the tumour to the anal verge, but there is evidence that this factor is not associated with age \[[@CR8]\]. We did not study this issue, but some authors have found a strong association between age and the use of radiotherapy regardless of tumour sub-site location \[[@CR7]\].

Limitations {#Sec11}
-----------

This study has some limitations that should be recognised. We were not able to contact nearly 9% of eligible patients, and we found that these patients were older than the participants; hence, the older patients included may be a biased sample of the older population. If the clinical status of participants was better than that of those excluded, we could be underestimating the real effect of age on the use of cancer treatments. Another selection bias could be associated with the type of centres included in the study, given that most of them were referral hospitals with specialised units.

Regarding comorbidity, it has been suggested that the CCI may not capture comorbidities well, as it does not measure the severity of comorbid conditions \[[@CR30]\]. To compensate for this limitation, at least partially, we included ASA class as a proxy for disease severity.

Apart from comorbidity, another factor that could justify a lower use of treatment in older people is a supposedly greater toxicity. There is some evidence suggesting a lack of association between age and toxicity \[[@CR31]\] or even a lower incidence of adverse effects in people above 75 years old \[[@CR32], [@CR33]\], attributable to dose reduction and the use of less aggressive treatment regimens in this age group. A recent Danish study found that over-70-year-olds with colorectal cancer were treated with single-agent therapy and at a lower initial dosage and that this chemotherapy dose reduction did not have an impact on disease-free survival or cancer-specific mortality; these outcomes were only different in the older patients who received less than half of the full number of cycles (given to other patients) \[[@CR11]\]. Nevertheless, other authors have described a higher level of toxicity with age \[[@CR2], [@CR34]\]. In the present study, we did not assess adverse events.

A weakness in determining the causes of the low adherence to clinical practice guidelines for older patients is the lack of information concerning the functional status of patients, which might explain treatment decisions. An alteration in the instrumental activities of daily living has been significantly associated with chemotherapy-related toxicity \[[@CR35]\]. Further, poor nutritional status has been described as a predictor of a lower tolerance to chemotherapy, and factors such as malnutrition and frailty have been associated with higher mortality in patients with colorectal cancer undergoing palliative chemotherapy \[[@CR36]\]. It would be of interest to know whether the 41 patients excluded because of functional limitations received chemo/radio-therapy but poor functional or cognitive status was used as exclusion criterion in the main study. In the case of radiotherapy, another factor that might hinder treatment is difficulty of access to treatment centres \[[@CR37]\], although we think that this factor would not have a great impact in our setting, given that when the distance to the hospital is large, public services provide transport to patients who need it.

In our study, we did not take into account variables such as the opinions of doctors and preferences of patients and their relatives. According to some authors, the opinions and attitudes of doctors may explain the low prescription of adjuvant chemotherapy. In particular, older patients are perceived as being less able to tolerate chemotherapy well \[[@CR38]\]. Additionally, doctors perceive that a short life expectancy may limit the benefits of chemotherapy, although it has also been shown that chemotherapy does increase the time to recurrence and overall survival in older patients \[[@CR11]\]. Some research has provided evidence that doctors may be less likely to offer adjuvant treatments to older patients \[[@CR39]\], and in terms of patient preferences, it has been reported that older patients more frequently decline adjuvant therapy, especially if they lack social support \[[@CR6], [@CR40]\]. Yellen et al. found that older patients were not less likely to accept chemotherapy than younger patients but that they were less willing to accept a greater level of toxicity in exchange for longer survival \[[@CR41]\].

In our health system, the odds of use of both adjuvant chemotherapy for colon cancer and preoperative radiotherapy for rectal cancer decrease dramatically with age. This conclusion can be partially but not completely explained by a higher frequency and severity of comorbidity among older patients. Nevertheless, curative resection, tumour characteristics and social factors such as deprivation, level of education and living arrangements did not help to explain the observed differences in treatment by age. Indeed, after adjusting for all these factors, significant differences between age groups remained. Further research is required to assess the impact of the functional, cognitive and motor status of patients as well as doctors' knowledge and attitudes and the preferences of patients and their relatives. Some studies have reported the usefulness of including geriatric assessment tools for daily clinical practice, although their application for identifying patients who are good candidates for adjuvant treatments is not clear, and further research is needed to assess the role of these tools in oncological treatment \[[@CR3], [@CR42]\].

Conclusions {#Sec12}
===========

The probability of older patients with colorectal cancer receiving adjuvant chemotherapy and preoperative radiotherapy is lower than that of younger patients and many of them are not receiving the treatments recommended by clinical practice guidelines. Differences in comorbidity, tumour characteristics, curative resection, and socioeconomic factors do not explain this lower probability of treatment. Research is needed to identify the role of physical and cognitive functional status, doctors' attitudes, and preferences of patients and their relatives, in the use of adjuvant therapies.
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ASA

:   American Society of Anesthesiologists

CAPOX

:   Capecitabine, Oxaliplatin

CCI

:   Charlson Comorbidity Index

CI

:   Confidence Interval

FOLFOX

:   5-Fluorouracil, Oxaliplatin

OR

:   Odds Ratio

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

We are grateful to the participating patients who voluntarily took part in this study. We also thank the doctors and all the interviewers from the participating hospitals (Antequera, Costa del Sol, Valme, Virgen del Rocío, Virgen de las Nieves, Canarias, Parc Taulí, Althaia Foundation, del Mar, Clínico San Carlos, La Paz, Infanta Sofía, Alcorcón Foundation, Galdakao-Usansolo, Araba, Basurto, Cruces, Donostia, Bidasoa, Mendaro, Zumárraga and Doctor Peset), for their invaluable collaboration in patient recruitment, and to the Research Committees of the participating hospitals.

The Results and Health Services Research in Colorectal Cancer (REDISECC- CARESS/CCR group):

Jose María Quintana^1^, Marisa Baré^2^, Maximino Redondo^3^, Eduardo Briones^4^, Nerea Fernández de Larrea^5^, Cristina Sarasqueta^6^, Antonio Escobar^7^, Francisco Rivas^8^, Maria Morales-Suárez^9^, Juan Antonio Blasco^10^, Isabel del Cura^11^, Inmaculada Arostegui^12^, Amaia Bilbao^7^, Nerea González^1^, Susana García-Gutiérrez^1^, Iratxe Lafuente^1^, Urko Aguirre^1^, Miren Orive Calzada^1^, Josune Martin^1^, Ane Antón-Ladislao^1^, Núria Torà^13^, Marina Pont^13^, María Purificación Martínez del^14^, Alberto Loizate^15^, Ignacio Zabalza^16^, José Errasti^17^, Antonio Gimeno^18^, Santiago Lázaro^19^, Mercè Comas^20^, Jose María Enríquez-Navascues^21^, Carlos Placer^21^, Amaia Perales^22^, Iñaki Urkidi^23^, Jose María Erro^24^, Enrique Cormenzana^25^, Adelaida Lacasta^26^, Pep Piera^26^, Elena Campano^27^, Ana Isabel Sotelo^28^, Segundo Gómez-Abril^29^, F. Medina-Cano^30^, Julia Alcaide^31^, Arturo Del Rey-Moreno^32^, Manuel Jesús Alcántara^33^, Rafael Campo^34^, Alex Casalots^35^, Carles Pericay^36^, Maria José Gil^37^, Miquel Pera^37^, Pablo Collera^38^, Josep Alfons Espinàs^39^, Mercedes Martínez^40^, Mireia Espallargues^41^, Caridad Almazán^42^, Paula Dujovne^43^, José María Fernández-Cebrián^43^, Rocío Anula^44^, Julio Mayol^44^, Ramón Cantero^45^, Héctor Guadalajara^46^, María Alexandra Heras^46^, Damián García^46^, Mariel Morey^47^, Alberto Colina^48^.

^1^Research Unit, Galdakao-Usansolo Hospital, Galdakao-Bizkaia/Health Services Research on Chronic Diseases Network (REDISSEC), Spain.

^2^Clinical Epidemiology and Cancer Screening, Corporació Sanitaria ParcTaulí,

Sabadell/REDISSEC, Spain.

^3^Laboratory Service, Costa del Sol Hospital, Málaga/REDISSEC, Spain.

^4^Epidemiology Unit, Seville Health District, Andalusian Health Service, Spain.

^5^Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain/Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.

^6^Research Unit, Donostia University Hospital/Biodonostia Health Research Institute, Donostia/REDISSEC, Spain.

^7^Research Unit, Basurto University Hospital, Bilbao/REDISSEC, Spain.

^8^Epidemiology Service, Costa del Sol Hospital, Málaga/REDISSEC, Spain.

^9^Department of Preventive Medicine and Public Health, University of Valencia/Epidemiology and Public Health Networking Biomedical Research Centre (CIBERESP) - Center for Public Health Research (CSISP) - Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.

^10^ Health Technology Assessment Unit, Laín Entralgo Agency, Madrid, Spain.

^11^Research and Teaching Support Unit, Teaching and Research Office, Planning Division, Primary Care Management, Madrid Regional Department of Health, Spain.

^12^Department of Applied Mathematics, Statistics and Operations Research, University of the Basque Country/REDISSEC, Spain.

^13^Clinical Epidemiology and Cancer Screening, Corporació Sanitaria ParcTaulí,

Sabadell/REDISSEC, Spain.

^14^Department of Medical Oncology, Basurto University Hospital, Bilbao, Spain.

^15^Department of General Surgery, Basurto University Hospital, Bilbao, Spain.

^16^Department of Histopathology, Galdakao-Usansolo Hospital, Galdakao, Spain.

^17^Department of General Surgery, Araba University Hospital, Vitoria-Gasteiz, Spain.

^18^Department of Gastroenterology, Canarias University Hospital, La Laguna, Spain.

^19^Department of General Surgery, Galdakao-Usansolo Hospital, Galdakao, Spain.

^20^Municipal Healthcare Institute (IMAS)-Hospital del Mar, Barcelona, Spain.

^21^Department of General and Digestive Surgery, Donostia University Hospital, Spain.

^22^Biodonostia Health Research Institute, Donostia, Spain.

^23^Department of General and Gastrointestinal Surgery, Mendaro Hospital, Spain.

^24^Department of General and Gastrointestinal Surgery, Zumárraga Hospital, Spain.

^25^Department of General and Gastrointestinal Surgery, Bidasoa Hospital, Spain.

^26^Department of Medical Oncology, Donostia University Hospital, Spain.

^27^Institute of Biomedicine of Seville (IBIS), Virgen del Rocío University Hospital, Sevilla, Spain.

^28^Department of Surgery, Virgen de Valme University Hospital, Sevilla, Spain.

^29^Department of General and Gastrointestinal Surgery, Hospital Dr.Peset, Valencia, Spain.

^30^Department of General and Gastrointestinal Surgery, Costa del Sol Health Agency, Marbella, Spain.

^31^Department of Medical Oncology, Costa del Sol Health Agency, Marbella, Spain.

^32^Department of Surgery, Antequera Hospital, Spain.

^33^Coloproctology Unit, General and Digestive Surgery Service, Corporació Sanitaria Parc Taulí, Sabadell, Spain.

^34^Digestive Diseases Department, Corporació Sanitaria Parc Taulí, Sabadell, Spain.

^35^Pathology Service, Corporació Sanitaria ParcTaulí, Sabadell, Spain.

^36^Medical Oncology Department, Corporació Sanitaria Parc Taulí, Sabadell/REDISSEC, Spain.

^37^General and Digestive Surgery Service, Parc de Salut Mar, Barcelona, Spain.

^38^General and Digestive Surgery Service, Althaia- Xarxa Assistencial Universitaria, Manresa, Spain.

^39^Catalonian Cancer Strategy Unit, Department of Health, Catalan Institute of Oncology (ICO), Barcelona.

^40^Medical Oncology Department, Catalan Institute of Oncology (ICO), Spain.

^41^Agency for Health Quality and Assessment of Catalonia (AquAS)/REDISSEC, Spain.

^42^Agency for Health Quality and Assessment of Catalonia (AQuAS)/CIBERESP, Spain.

^43^Department of General and Gastrointestinal Surgery, Alcorcón Foundation University Hospital, Madrid, Spain.

^44^Department of General and Gastrointestinal Surgery, San Carlos University Hospital, Madrid, Spain.

^45^Department of General and Gastrointestinal Surgery, Infanta Sofía University Hospital, San Sebastián de los Reyes, Madrid, Spain.

^46^Department of General and Gastrointestinal Surgery, La Paz University Hospital, Madrid, Spain.

^47^REDISSEC. Research Support Unit, Primary Care Management for the Madrid Region, Madrid, Spain.

^48^Department of General Surgery and Digestive Diseases, Cruces University Hospital, Barakaldo, Spain.

Study concepts and design: SC, QJM and REDISSEC-CARESS/CCR group. Data acquisition: SC, PA, EA, BM, RM, FN, BE, QJM and REDISSEC-CARESS/CCR group. Quality control of data and algorithms: SC, PA, QJM. Data analysis and interpretation: SC, PA, PJM and ZMV. Manuscript preparation: SC and ZMV. All authors reviewed and approved the final version of the manuscript.

This work was supported in part by grants from the Spanish Health Research Fund (PS09/00314, PS09/00910, PS09/00746, PS09/00805, PI09/90460, PI09/90490, PI09/90397, PI09/90453, PI09/90441); Department of Health of the Basque Country (2010111098); KRONIKGUNE--Research Centre on Chronicity (KRONIK 11/006); and the European Regional Development Fund. These institutions had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; nor in the decision to submit the paper for publication.

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

This project was approved by the following bodies in Spain (reference number of approval, when provided, in brackets): the Ethics Committees of Txagorritxu (2009--20), Galdakao, Donostia (5/09), Basurto, La Paz, Clínico San Carlos, Fundación Alcorcón and Marbella (10/09) hospitals, and the Ethics Committee of the Basque Country (PI2014084). All patients were informed of the objectives of the study and invited to voluntarily participate. Patients who agreed to participate provided written consent.

Not applicable

The authors declare that they have no competing interests.
